sarpogrelate

Ligand id: 210

Name: sarpogrelate

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 14
Topological polar surface area 85.3
Molecular weight 429.22
XLogP 4.51
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
May be used to reduce the risk of pathological thrombosis (clotting) in small and medium arteries and veins in many diseases including diabetes mellitus, Buerger's disease, Raynaud's disease, coronary artery disease, angina pectoris, and atherosclerosis. There is no information regarding approval for clinical use of this drug on the US FDA or European Medicines Agency websites. Individual national approval agencies may have granted marketing authorisation (principally South Korea and Japan).
Mechanism Of Action and Pharmacodynamic Effects
This drug blocks serotonin-induced platelet aggregation by antagonising the 5-HT2A and 5-HT2B receptors [1-3].